Ipamorelin side effects

What the one trial in patients recorded

The trial was run to see whether ipamorelin could restart the gut after a bowel operation. It was “The design was a multicenter, double-blind, placebo-controlled, clinical trial.” in “The patients were adults undergoing small and large bowel resection by open or laparoscopic surgery.”¹ — people already recovering from surgery, which is why the adverse-event rate is high in both arms.

Read the two figures together and the picture is not a peptide causing trouble; it is a group of post-surgical patients having a hard week either way, slightly fewer of them in the treated arm. The authors’ own conclusion says ipamorelin “twice daily for up to 7 days was well tolerated”.¹

They also drew their own limits: “This proof of concept study was small and enrolled patients with a broad range of underlying conditions.”¹ A small trial in a mixed group of surgical patients tells you what happened over a week in hospital. It was never built to tell anyone what happens over a season of injections in a healthy adult.

What the FDA says, and about which route

Ipamorelin acetate sits in category 2 of the bulk substances nominated for compounding, which the agency defines on the page itself: “Bulk drug substances that may present significant safety risks have been placed in category 2 under the interim policies.”² Its entry gives three reasons, and the third is the one that matters here:

The study it refers to is the one above. Two documents, one trial, two descriptions — and this page prints both rather than choosing. What the agency and the authors do agree on is the route: the deaths and the tolerability both belong to intravenous use in hospital, not to anything a reader is likely to be comparing.

The other two reasons are about the substance itself. Compounded drugs containing it “Compounded drugs containing Ipamorelin acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities.”, and the agency adds that it “Ipamorelin acetate also contains unnatural amino acids, which add to the complexity of peptide characterization.”² Both are arguments about what can be in a vial, which is a different question from what the molecule does. Which CJC-1295 are you buying follows that thread for the other half of the usual pairing.

What has never been measured

Searching PubMed for ipamorelin alongside adverse events, safety, tolerability or side effects returns eleven records. One is the trial above, one is a study in rats, and the remaining nine are reviews published in 2026 — papers summarizing the same small pile rather than adding to it.

The most recent of those reviews says so directly, putting against ipamorelin: “Generally favourable tolerability with no significant common adverse effects reported compared to GH therapy; no long term safety data available”³ It also warns against reading its own shorthand too firmly, noting that “Descriptors reflect the strength and consistency of available human data, not a formal grading scheme.”³

The pairing sellers list adds a second unmeasured thing to the first. No published study has given CJC-1295 and ipamorelin to people together, which is CJC-1295 safe sets out with its own census, and the results timeline covers what each molecule has been timed at separately.

The hormones that stayed still

The side effect most people ask about is the one the older peptides in this family are known for: a rise in cortisol and prolactin. The 1998 paper that named ipamorelin tested exactly that, and the comparators did move — “Administration of both GHRP-6 and GHRP-2 resulted in increased plasma levels of ACTH and cortisol.”⁴ Against that background its own result stands out, and it is a comparison rather than a zero:

Prolactin was flatter still: “None of the GH secretagogues tested affected FSH, LH, PRL or TSH plasma levels.”⁴ And the margin was wide — “This lack of effect on ACTH and cortisol plasma levels was evident even at doses more than 200-fold higher than the ED50 for GH release.”⁴ All of it was measured in pigs, “The specificity for GH release was studied in swine.”⁴

The 2026 review carries the same distinction forward in people while choosing a weaker word, observing that stress-hormone and prolactin rises are “ACTH/cortisol and prolactin elevations are largely a feature of earlier ghrelin-mimetic GHRPs (GHRP-2, GHRP-6, hexarelin), with ipamorelin notably sparing”.³ Sparing is not the same as none, and does ipamorelin raise cortisol is the page that takes both sentences apart.

Questions that come next

Sources